HC Wainwright Forecasts Strong Price Appreciation for TG Therapeutics (NASDAQ:TGTX) Stock

TG Therapeutics (NASDAQ:TGTX) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for TG Therapeutics’ Q4 2024 earnings at $0.15 EPS, FY2024 earnings at $0.07 EPS, FY2025 earnings at $1.17 EPS and FY2026 earnings at $1.77 EPS.

A number of other equities analysts have also weighed in on TGTX. TD Cowen started coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective on the stock. B. Riley lifted their target price on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

TG Therapeutics Price Performance

Shares of NASDAQ:TGTX opened at $28.81 on Tuesday. TG Therapeutics has a one year low of $9.81 and a one year high of $28.92. The stock has a market capitalization of $4.46 billion, a price-to-earnings ratio of -288.07 and a beta of 2.19. The company has a 50-day simple moving average of $23.84 and a 200-day simple moving average of $20.46. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.65%. The company had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. During the same quarter last year, the firm earned $0.73 EPS. The business’s revenue was down 49.4% on a year-over-year basis. On average, analysts predict that TG Therapeutics will post 0.13 EPS for the current year.

Hedge Funds Weigh In On TG Therapeutics

A number of large investors have recently made changes to their positions in TGTX. NBC Securities Inc. grew its position in TG Therapeutics by 58.9% during the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 485 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in shares of TG Therapeutics during the 2nd quarter worth approximately $35,000. Blue Trust Inc. boosted its stake in shares of TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new stake in shares of TG Therapeutics in the 3rd quarter worth approximately $53,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in TG Therapeutics in the 1st quarter valued at approximately $58,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.